Study of cell therapy for rheumatoid arthritis and Sjogren's disease
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new cell therapy (Rapcabtagene Autoleucel) to see if it's safe and might help people with rheumatoid arthritis or Sjogren's disease who haven't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old
- You must have a diagnosis of rheumatoid arthritis or Sjogren's disease with active symptoms
- Standard treatments for your condition must have not worked well enough
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study
- You must not have a history of cancer or organ transplant
- You must not have a serious active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
This trial tests a cell therapy called UTAA91 for people with severe rheumatoid arthritis that hasn't improved with standard treatments. It aims to see if this approach can help when other options have failed.
This trial tests a new type of cell therapy (SCAR02) that targets two proteins on immune cells to help calm down overactive autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis. It may be an option if standard treatments haven't worked well enough.
Hear when a new Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.